{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:35:32Z","timestamp":1787841332080,"version":"build-2784847793"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,13]],"date-time":"2020-03-13T00:00:00Z","timestamp":1584057600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Primary myelofibrosis (PMF) is a subtype of BCR-ABL1 negative myeloproliferative neoplasm. Its characteristic features include clonal myeloproliferation, dysregulation of kinase signaling pathway, abnormal release of cytokines leading to fibrosis in the bone marrow, osteosclerosis, and extramedullary hematopoiesis. Approximately 20% of deaths occur because of disease progression, but death may also result occur because of cardiovascular complications or as a consequence of either infection or bleeding. The only and curative option for PMF is allogeneic hematopoietic stem cell transplant (allo-HSCT); however, the Janus kinase (JAK) 1\/2 inhibitor ruxolitinib is highly effective in reducing constitutional symptoms and spleen volume, and has been found to improve survival. Ruxolitinib decreases the activity of type I T-helper cells, leading to decreased release of cytokines including tumor necrosis factor-\u03b1, interleukin-1 (IL-1), IL- 6, interferon-\u03b3, and production of IL-12, which can be a risk factor for opportunistic infections. In this report, we describe three cases of tuberculosis reactivation shortly after initiation of ruxolitinib therapy followed by a literature review.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.hemonc.2020.02.003","type":"journal-article","created":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T03:12:12Z","timestamp":1584328332000},"page":"252-256","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Reactivation of tuberculosis following ruxolitinib therapy for primary myelofibrosis"],"prefix":"10.4103","volume":"14","author":[{"given":"Farhan","family":"Khalid","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moussab","family":"Damlaj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohsen","family":"AlZahrani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadega A.","family":"Abuelgasim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giamal Edin","family":"Gmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-11-20241211","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"R2-11-20241211","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1182\/blood-2014-07-575373","article-title":"How I treat myelofibrosis","volume":"124","author":"Cervantes","year":"2014","journal-title":"Blood"},{"key":"R3-11-20241211","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1002\/ajh.24592","article-title":"Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"R4-11-20241211","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3109\/10428194.2014.963082","article-title":"Pulmonary tuberculosis reactivation following ruxolitinib treatment in a patient with primary myelofibrosis","volume":"56","author":"Chen","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"R5-11-20241211","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1038\/leu.2014.104","article-title":"Disseminated tuberculosis associated with ruxolitinib","volume":"28","author":"Hopman","year":"2014","journal-title":"Leukemia"},{"key":"R6-11-20241211","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"New Engl J Med"},{"key":"R7-11-20241211","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1182\/blood-2004-07-2864","article-title":"Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases","volume":"105","author":"Mesa","year":"2005","journal-title":"Blood"},{"key":"R8-11-20241211","first-page":"284168","article-title":"Ruxolitinib associated tuberculosis presenting as a neck lump","volume":"2015","author":"Shamil","year":"2015","journal-title":"Case Rep Infect Dis"},{"key":"R9-11-20241211","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"R10-11-20241211","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2010","journal-title":"J Clin Oncol"},{"key":"R11-11-20241211","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00277-014-2183-0","article-title":"Ruxolitinib-associated tuberculosis: a case of successful ruxolitinib rechallenge","volume":"94","author":"Palandri","year":"2015","journal-title":"Ann Hematol"},{"key":"R12-11-20241211","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1378\/chest.12-1604","article-title":"An opportunistic infection associated with ruxolitinib, a novel janus kinase 1, 2 inhibitor","volume":"143","author":"Wysham","year":"2013","journal-title":"Chest"},{"key":"R13-11-20241211","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1186\/1756-0500-5-552","article-title":"Disseminated tuberculosis in a patient treated with a JAK2 selective inhibitor: a case report","volume":"5","author":"Colomba","year":"2012","journal-title":"BMC Res Notes"},{"key":"R14-11-20241211","doi-asserted-by":"crossref","first-page":"3843","DOI":"10.1182\/blood-2013-10-531103","article-title":"Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?","volume":"122","author":"Heine","year":"2013","journal-title":"Blood"},{"key":"R15-11-20241211","first-page":"1596","article-title":"Efficacy of ruxolitinib in Korean myelofibrosis patients and cases complicated TB lymphadenitis during the treatment","volume":"122","author":"Lee","year":"2013","journal-title":"Am Soc Hematol"},{"key":"R16-11-20241211","doi-asserted-by":"crossref","first-page":"652","DOI":"10.5455\/ijmsph.2017.0846912092016","article-title":"Ruxolitinib-associated tuberculosis-a rare complication of a novel drug!","volume":"6","author":"Patil","year":"2017","journal-title":"Int J Med Sci Public Health"},{"key":"R17-11-20241211","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1182\/blood-2013-02-485888","article-title":"Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis","volume":"122","author":"Cervantes","year":"2013","journal-title":"Blood"},{"key":"R18-11-20241211","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/leu.2013.235","article-title":"Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis","volume":"28","author":"Caocci","year":"2014","journal-title":"Leukemia"},{"key":"R19-11-20241211","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1056\/NEJMc1302895","article-title":"Bilateral toxoplasmosis retinitis associated with ruxolitinib","volume":"369","author":"Goldberg","year":"2013","journal-title":"New Engl J Med"},{"key":"R20-11-20241211","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJMc1302135","article-title":"Progressive multifocal leukoencephalopathy associated with ruxolitinib","volume":"369","author":"Wathes","year":"2013","journal-title":"New Engl J Med"},{"key":"R21-11-20241211","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"R22-11-20241211","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7326\/0003-4819-107-6-843","article-title":"Benefit-risk considerations in preventive treatment for tuberculosis in elderly persons","volume":"107","author":"Stead","year":"1987","journal-title":"Ann Intern Med"},{"key":"R23-11-20241211","first-page":"2389038","article-title":"Reactivation of pulmonary tuberculosis following treatment of myelofibrosis with ruxolitinib","volume":"2016","author":"Abidi","year":"2016","journal-title":"Case Rep Hematol"},{"key":"R24-11-20241211","first-page":"A8650","article-title":"Fatal tuberculosis during treatment with ruxolitinib","volume":"159","author":"Keizer","year":"2015","journal-title":"Ned Tijdschr Geneeskd"},{"key":"R25-11-20241211","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"New Engl J Med"}],"container-title":["Hematology\/Oncology and Stem Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300327?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1658387620300327?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.02.003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:50:11Z","timestamp":1787838611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1016\/j.hemonc.2020.02.003"}},"subtitle":["Case series and literature review"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1016\/j.hemonc.2020.02.003","relation":{},"ISSN":["1658-3876"],"issn-type":[{"value":"1658-3876","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}